Effects of Indralin on Immunohematological Parameters and DNA Damage in Irradiated ICR (CD-1) Outbred Mice
- Авторлар: Bushmanov A.Y.1, Osipov A.N.1,2, Ignatov M.A.1, Vorontsova M.D.1, Karaulova T.A.1, Gordeev A.V.1, Yashkina E.I.1, Nikitenko O.V.1,3, Bychkova T.M.1,3, Stavrakova N.M.1, Andrianova I.E.1, Blokhina T.M.1,2, Vorobyeva N.Y.1,2, Ivanov A.A.1,3,4
-
Мекемелер:
- State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency
- Semenov Institute of Chemical Physics, Russian Academy of Sciences
- Federal State Budgetary Institution of Science “Russian Federation State Scientific Center—Institute of Biomedical Problems,” Russian Academy of Sciences
- Joint Institute for Nuclear Research
- Шығарылым: Том 46, № 11 (2019)
- Беттер: 1564-1570
- Бөлім: Modification of Radiation Effects
- URL: https://ogarev-online.ru/1062-3590/article/view/183391
- DOI: https://doi.org/10.1134/S1062359019110104
- ID: 183391
Дәйексөз келтіру
Аннотация
Abstract—Intragastric administration of radioprotector indralin (B-190 drug) to outbred SPF ICR (CD-1) mice 15 minutes before X-ray irradiation at doses of 6 Gy (LD-10/30), 6.5 Gy, and 7 Gy (LD-100/30) increases the 30-day survival of the animals and positively affects the state of the central organs of immunity and hematopoiesis, as well as the number of peripheral blood leukocytes. In addition, a positive effect on the behavioral reactions of the irradiated animals and striated muscles strength was noted. In addition to these secondary features of the indralin positive effect, a significant reduction of radiation-induced DNA damage in spleenocytes was observed using flow cytometry analysis of phosphorylated histone Н2АХ (γН2АХ) (1 h and eight days after X-ray irradiation) and DNA-comet assay (eight days after X-ray irradiation). The abovementioned methods are recommended for experiments investigating the influence of radioprotective drugs on DNA damage induction and repair in the irradiated organism, as well as for initial searching of potential radioprotectors and assessment of their effectiveness level in clinical practice and experiments.
Негізгі сөздер
Авторлар туралы
A. Bushmanov
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency
Email: a1931192@mail.ru
Ресей, Moscow
A. Osipov
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency; Semenov Institute of Chemical Physics, Russian Academy of Sciences
Email: a1931192@mail.ru
Ресей, Moscow; Moscow
M. Ignatov
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency
Email: a1931192@mail.ru
Ресей, Moscow
M. Vorontsova
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency
Email: a1931192@mail.ru
Ресей, Moscow
T. Karaulova
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency
Email: a1931192@mail.ru
Ресей, Moscow
A. Gordeev
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency
Email: a1931192@mail.ru
Ресей, Moscow
E. Yashkina
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency
Email: a1931192@mail.ru
Ресей, Moscow
O. Nikitenko
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency; Federal State Budgetary Institution of Science “Russian Federation State Scientific Center—Institute of Biomedical Problems,” Russian Academy of Sciences
Email: a1931192@mail.ru
Ресей, Moscow; Moscow
T. Bychkova
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency; Federal State Budgetary Institution of Science “Russian Federation State Scientific Center—Institute of Biomedical Problems,” Russian Academy of Sciences
Email: a1931192@mail.ru
Ресей, Moscow; Moscow
N. Stavrakova
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency
Email: a1931192@mail.ru
Ресей, Moscow
I. Andrianova
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency
Email: a1931192@mail.ru
Ресей, Moscow
T. Blokhina
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency; Semenov Institute of Chemical Physics, Russian Academy of Sciences
Email: a1931192@mail.ru
Ресей, Moscow; Moscow
N. Vorobyeva
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency; Semenov Institute of Chemical Physics, Russian Academy of Sciences
Email: a1931192@mail.ru
Ресей, Moscow; Moscow
A. Ivanov
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency; Federal State Budgetary Institution of Science “Russian Federation State Scientific Center—Institute of Biomedical Problems,” Russian Academy of Sciences; Joint Institute for Nuclear Research
Хат алмасуға жауапты Автор.
Email: a1931192@mail.ru
Ресей, Moscow; Moscow; Dubna
Қосымша файлдар
